Who We Are
Leadership
Partnership
Our Science
Therapeutic Areas
Duchenne
Hunter Syndrome
EGPA
Scientific Approach
Exon-Skipping
Gene Therapy
Selective JAK1 Inhibition
Pipeline & Products
Products
Clinical Trials
Newsroom
Events & Posters
Press Releases
Careers
Our Culture
Contact Us
Press releases
July 30, 2026
NS Pharma Parent Company, Nippon Shinyaku, Exercises Option Rights for Commercialization of AB2 Bio’s Tadekinig alfa in the U.S.
Read More
June 26, 2026
Nippon Shinyaku and Elixirgen Therapeutics Enter Option Agreement for Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy
Read More
June 23, 2026
NS Pharma Parent Company, Nippon Shinyaku, Announces Sponsored Research Agreement with Boston Children’s Hospital
Read More
March 9, 2026
Brogidirsen (NS-089/NCNP-02) 4.5-Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at 2026 MDA Clinical & Scientific Conference
Read More
October 14, 2025
Brogidirsen (NS-089/NCNP-02) 3.5 Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at 2025 World Muscle Society Congress
Read More
September 19, 2025
FDA Grants Orphan Drug Designation to NS-051/NCNP-04 for the Treatment of Duchenne Muscular Dystrophy
Read More
September 9, 2025
FDA Grants Fast Track Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis
Read More
July 1, 2025
NS Pharma Announces Strategic Alliance with Boston Children’s Hospital to Develop New Therapies for Rare Diseases
Read More
Show more
